Literature DB >> 8038237

Kaposi's sarcoma in an HIV-negative CLL patient as the cause of thrombocytopenia.

P W Wijermans1, K van Groningen, E A van Royen, J A Bruijn.   

Abstract

A patient is described with a rapidly progressive Kaposi's sarcoma following immunosuppressive therapy with fludarabine monophosphate (FAMP) for chronic lymphocytic leukemia. The development of this tumor was accompanied by progressive thrombocytopenia, due to trapping of the platelets in the Kaposi sarcoma, without signs of consumptive coagulopathy or microangiopathic hemolytic anemia. This sequestration process might be caused by the abnormal structure of the tumoral vessels, leading to exposure of subendothelial structures like collagen, von Willebrand's factor, and tenascin to the vessel lumen. A severe immunosuppression due to the lymphocytotoxic effect of FAMP on several T-cell subpopulations was seen. This case confirms the importance of immunosuppression as a co-factor in the development of Kaposi's sarcoma also in HIV-negative patients, and adds Kaposi's sarcoma to the differential diagnosis of thrombocytopenia in immunosuppressed patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8038237     DOI: 10.1007/bf01695038

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  16 in total

1.  Lymphadenopathic type of Kaposi's sarcoma presenting with generalized petechial hemorrhages. A case report from Taiwan.

Authors:  I J Su; T T Kuo; S Y Wu; I J Hung
Journal:  Cancer       Date:  1984-09-01       Impact factor: 6.860

2.  Kaposi's sarcoma and immunosuppressive therapy: an appraisal.

Authors:  R W Gange; E W Jones
Journal:  Clin Exp Dermatol       Date:  1978-06       Impact factor: 3.470

3.  Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men--New York City and California.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1981-07-03       Impact factor: 17.586

4.  Association of Kaposi's sarcoma with second primary malignancies: possible etiopathogenic implications.

Authors:  B Safai; V Miké; G Giraldo; E Beth; R A Good
Journal:  Cancer       Date:  1980-03-15       Impact factor: 6.860

5.  Severe immunodeficiency in patients treated with fludarabine monophosphate.

Authors:  P W Wijermans; W B Gerrits; H L Haak
Journal:  Eur J Haematol       Date:  1993-05       Impact factor: 2.997

6.  Kaposiform hemangioendothelioma of infancy and childhood. An aggressive neoplasm associated with Kasabach-Merritt syndrome and lymphangiomatosis.

Authors:  L R Zukerberg; B J Nickoloff; S W Weiss
Journal:  Am J Surg Pathol       Date:  1993-04       Impact factor: 6.394

7.  Kaposi's sarcoma in organ transplant recipients: report of 20 cases.

Authors:  I Penn
Journal:  Transplantation       Date:  1979-01       Impact factor: 4.939

8.  Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia.

Authors:  L Bergmann; K Fenchel; B Jahn; P S Mitrou; D Hoelzer
Journal:  Ann Oncol       Date:  1993-05       Impact factor: 32.976

9.  Identification of a new cell adhesion motif in two homologous peptides from the COOH-terminal cell binding domain of human thrombospondin.

Authors:  M D Kosfeld; W A Frazier
Journal:  J Biol Chem       Date:  1993-04-25       Impact factor: 5.157

Review 10.  The importance of blood cell-vessel wall interactions in tumour metastasis.

Authors:  A Poggi; M Stella; M B Donati
Journal:  Baillieres Clin Haematol       Date:  1993-09
View more
  2 in total

1.  Kaposi sarcoma after corticosteroid therapy for idiopathic thrombocytopenic purpura.

Authors:  Kwang Hyun Choi; Jae Ho Byun; Jun Young Lee; Baik Kee Cho; Hyun Jeong Park
Journal:  Ann Dermatol       Date:  2009-08-31       Impact factor: 1.444

2.  Admitted AIDS-associated Kaposi sarcoma patients: Indications for admission and predictors of mortality.

Authors:  Faheema Vally; Wencilaus Margret Pious Selvaraj; Owen Ngalamika
Journal:  Medicine (Baltimore)       Date:  2020-09-25       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.